CN112236424B - 经烷氧基取代的吡啶基衍生物 - Google Patents
经烷氧基取代的吡啶基衍生物 Download PDFInfo
- Publication number
- CN112236424B CN112236424B CN201980036967.6A CN201980036967A CN112236424B CN 112236424 B CN112236424 B CN 112236424B CN 201980036967 A CN201980036967 A CN 201980036967A CN 112236424 B CN112236424 B CN 112236424B
- Authority
- CN
- China
- Prior art keywords
- alkylene
- difluoromethoxy
- isopropylphenyl
- methylpyridin
- azetidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2018/065016 | 2018-06-07 | ||
| EP2018065016 | 2018-06-07 | ||
| PCT/EP2019/064690 WO2019234115A1 (en) | 2018-06-07 | 2019-06-05 | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112236424A CN112236424A (zh) | 2021-01-15 |
| CN112236424B true CN112236424B (zh) | 2024-03-15 |
Family
ID=66912779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980036967.6A Active CN112236424B (zh) | 2018-06-07 | 2019-06-05 | 经烷氧基取代的吡啶基衍生物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12344597B2 (enExample) |
| EP (1) | EP3802517B1 (enExample) |
| JP (1) | JP7386183B2 (enExample) |
| KR (1) | KR102826034B1 (enExample) |
| CN (1) | CN112236424B (enExample) |
| AU (1) | AU2019282274A1 (enExample) |
| BR (1) | BR112020024879A2 (enExample) |
| CA (1) | CA3102683A1 (enExample) |
| DK (1) | DK3802517T3 (enExample) |
| EA (1) | EA202092955A1 (enExample) |
| ES (1) | ES2940695T3 (enExample) |
| FI (1) | FI3802517T3 (enExample) |
| HR (1) | HRP20230243T1 (enExample) |
| HU (1) | HUE061559T2 (enExample) |
| LT (1) | LT3802517T (enExample) |
| MX (1) | MX2020013291A (enExample) |
| PL (1) | PL3802517T3 (enExample) |
| PT (1) | PT3802517T (enExample) |
| RS (1) | RS63990B1 (enExample) |
| SI (1) | SI3802517T1 (enExample) |
| TW (1) | TW202016090A (enExample) |
| WO (1) | WO2019234115A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119162A1 (es) * | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| WO2021110805A1 (en) * | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| FI20225388A1 (en) * | 2022-05-05 | 2023-11-06 | Equinorm Ltd | New heterocyclic compounds, preparation methods and their uses |
| WO2025169931A1 (ja) * | 2024-02-05 | 2025-08-14 | Ｕｂｅ株式会社 | カルボキサミド化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088908A2 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Heterocyclo inhibitors of potassium channel function |
| EP2481725A1 (en) * | 2009-09-25 | 2012-08-01 | Astellas Pharma Inc. | Substituted amide compound |
| CN105189481A (zh) * | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130088C (enExample) | 1960-03-14 | |||
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| AU7961300A (en) | 1999-10-29 | 2001-05-14 | Yamanouchi Pharmaceutical Co., Ltd. | Kainic acid neurocytotoxicity inhibitors |
| AU2001262185A1 (en) | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US7435824B2 (en) | 2002-04-19 | 2008-10-14 | Bristol-Myers Squibb Company | Prodrugs of potassium channel inhibitors |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| SG146624A1 (en) | 2003-09-11 | 2008-10-30 | Kemia Inc | Cytokine inhibitors |
| WO2005037269A1 (ja) | 2003-10-21 | 2005-04-28 | Dainippon Sumitomo Pharma Co., Ltd. | 新規ピペリジン誘導体 |
| EP1687296A1 (en) | 2003-11-18 | 2006-08-09 | Warner-Lambert Company LLC | Antibacterial aminoquinazolidinedione derivatives |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| TWI377198B (en) | 2005-08-24 | 2012-11-21 | Eisai R&D Man Co Ltd | Novel pyridine derivatives and pyrimidine derivatives (3) |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| JP5164510B2 (ja) | 2006-10-06 | 2013-03-21 | 日本曹達株式会社 | 含窒素複素環化合物および有害生物防除剤 |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| AU2008311971A1 (en) | 2007-10-18 | 2009-04-23 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| EP2297153B1 (en) | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| AU2009243756B2 (en) | 2008-05-05 | 2013-06-27 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| BRPI0918971A2 (pt) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | tienopirimidinas para composições farmacêuticas |
| ES2682303T3 (es) | 2010-08-05 | 2018-09-19 | Zoetis Services Llc | Derivados de isoxazolina como agentes antiparasitarios |
| TW201305178A (zh) | 2010-10-29 | 2013-02-01 | Glenmark Pharmaceuticals Sa | 作為ｍＰＧＥＳ－１抑制物的三環化合物 |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| EP2651930B1 (en) | 2010-12-16 | 2015-10-28 | Boehringer Ingelheim International GmbH | Biarylamide inhibitors of leukotriene production |
| PT2683723T (pt) | 2011-03-10 | 2016-08-05 | Zoetis Services Llc | Derivados espirocíclicos de isoxazolina como agentes antiparasitários |
| JP2015506349A (ja) | 2011-12-21 | 2015-03-02 | アルデリックス， インコーポレイテッド | 非全身性ｔｇｒ５アゴニスト |
| WO2014079805A1 (en) | 2012-11-23 | 2014-05-30 | Boehringer Ingelheim International Gmbh | Pyrazole compounds for treating hairloss |
| AR108185A1 (es) | 2016-04-06 | 2018-07-25 | Abbvie Inc | Amidas terciarias y método para su uso |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
-
2019
- 2019-06-05 HU HUE19731163A patent/HUE061559T2/hu unknown
- 2019-06-05 CN CN201980036967.6A patent/CN112236424B/zh active Active
- 2019-06-05 HR HRP20230243TT patent/HRP20230243T1/hr unknown
- 2019-06-05 PL PL19731163.2T patent/PL3802517T3/pl unknown
- 2019-06-05 PT PT197311632T patent/PT3802517T/pt unknown
- 2019-06-05 EP EP19731163.2A patent/EP3802517B1/en active Active
- 2019-06-05 TW TW108119605A patent/TW202016090A/zh unknown
- 2019-06-05 FI FIEP19731163.2T patent/FI3802517T3/fi active
- 2019-06-05 ES ES19731163T patent/ES2940695T3/es active Active
- 2019-06-05 SI SI201930472T patent/SI3802517T1/sl unknown
- 2019-06-05 US US16/972,878 patent/US12344597B2/en active Active
- 2019-06-05 RS RS20230148A patent/RS63990B1/sr unknown
- 2019-06-05 DK DK19731163.2T patent/DK3802517T3/da active
- 2019-06-05 JP JP2020567808A patent/JP7386183B2/ja active Active
- 2019-06-05 WO PCT/EP2019/064690 patent/WO2019234115A1/en not_active Ceased
- 2019-06-05 MX MX2020013291A patent/MX2020013291A/es unknown
- 2019-06-05 LT LTEPPCT/EP2019/064690T patent/LT3802517T/lt unknown
- 2019-06-05 AU AU2019282274A patent/AU2019282274A1/en not_active Abandoned
- 2019-06-05 EA EA202092955A patent/EA202092955A1/ru unknown
- 2019-06-05 KR KR1020217000125A patent/KR102826034B1/ko active Active
- 2019-06-05 BR BR112020024879-7A patent/BR112020024879A2/pt not_active IP Right Cessation
- 2019-06-05 CA CA3102683A patent/CA3102683A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088908A2 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Heterocyclo inhibitors of potassium channel function |
| EP2481725A1 (en) * | 2009-09-25 | 2012-08-01 | Astellas Pharma Inc. | Substituted amide compound |
| CN105189481A (zh) * | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102826034B1 (ko) | 2025-06-27 |
| KR20210018900A (ko) | 2021-02-18 |
| CN112236424A (zh) | 2021-01-15 |
| BR112020024879A2 (pt) | 2021-03-09 |
| CA3102683A1 (en) | 2019-12-12 |
| WO2019234115A1 (en) | 2019-12-12 |
| JP7386183B2 (ja) | 2023-11-24 |
| AU2019282274A1 (en) | 2021-01-28 |
| EA202092955A1 (ru) | 2021-04-08 |
| FI3802517T3 (fi) | 2023-03-23 |
| PL3802517T3 (pl) | 2023-05-22 |
| US12344597B2 (en) | 2025-07-01 |
| US20210246116A1 (en) | 2021-08-12 |
| TW202016090A (zh) | 2020-05-01 |
| LT3802517T (lt) | 2023-03-10 |
| EP3802517B1 (en) | 2022-12-21 |
| MX2020013291A (es) | 2021-04-29 |
| ES2940695T3 (es) | 2023-05-10 |
| RS63990B1 (sr) | 2023-03-31 |
| HRP20230243T1 (hr) | 2023-04-14 |
| JP2021527046A (ja) | 2021-10-11 |
| HUE061559T2 (hu) | 2023-07-28 |
| EP3802517A1 (en) | 2021-04-14 |
| PT3802517T (pt) | 2023-03-20 |
| DK3802517T3 (da) | 2023-03-13 |
| SI3802517T1 (sl) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7441264B2 (ja) | Ｊａｋファミリーのキナーゼの阻害剤としてのイミダゾピロロピリジン | |
| JP7600433B2 (ja) | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 | |
| CN112055711B (zh) | 作为lpa拮抗剂的环己基酸三唑吖嗪类 | |
| EA039808B1 (ru) | Аминотриазолопиридины в качестве ингибиторов киназ | |
| JP7386183B2 (ja) | Ｌｐａ１受容体アンタゴニストとしてのアルコキシ置換ピリジニル誘導体及び繊維症の治療におけるその使用 | |
| EA023287B1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов св2 | |
| CN114599648A (zh) | 作为lpa拮抗剂的三唑羧酸 | |
| CN114026082B (zh) | 吡啶-3-基衍生物 | |
| WO2025137541A1 (en) | Kinase modulators and methods of use thereof | |
| TW202229239A (zh) | 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物 | |
| HK40066271A (en) | Pyridin-3-yl derivatives | |
| HK40066271B (en) | Pyridin-3-yl derivatives | |
| EA040901B1 (ru) | Алкокси-замещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза | |
| EA047605B1 (ru) | Пиридин-3-ильные производные | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
| JP2011088888A (ja) | ヒドロキシキノキサリンカルボキサミド誘導体を含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |